China Biopharmaceuticals 2017 Annual Report: 32 products sold over 100 million yuan

Source: Medical magic cube data 2018-03-26 China biopharmaceutical announced its 2017 performance on March 23, making remarkable achievements with its flexible marketing strategy and strong R & D strength According to the annual report, as of December 31, 2017, China biopharmaceutical's annual revenue was 14.819 billion yuan (+ 9.4%), and its profit was 2.171 billion yuan (+ 32.6%) China's biopharmaceutical products are mainly concentrated in liver disease, tumor, cardiovascular, orthopedics, parenteral nutrition, infectious diseases, respiratory diseases and other fields, of which liver disease drugs are still the pillar of its revenue, contributing 6.543 billion yuan of revenue, accounting for 44.2% of the group's revenue Next are analgesics, tumor drugs and cardiovascular drugs In 2017, the annual sales revenue of 32 biopharmaceutical products in China exceeded 100 million yuan, 4 more than that in 2016 Among them, Runzhong (entecavir dispersible tablets), Tianqing Ganmei (magnesium isoglycate injection), KAIFEN (flurbiprofen ester injection) and Kaishi (qianliedil injection) were more than 1 billion yuan The stable growth performance of China biopharmaceutical's product sales in 2017 (billion yuan) is closely related to the strong marketing strength of China biopharmaceutical As of December 31, 2017, China biopharmaceutical group had 18649 employees, including more than 11000 professional sales personnel, accounting for nearly 60%, covering more than 90% of hospitals nationwide Of course, the R & D strength of China's biopharmaceuticals is also first-class in China, with 10 R & D bases and more than 2000 R & D personnel, accounting for about 11%; in 2017, the R & D expenditure was 1.595 billion yuan, accounting for 10.8% of the group's revenue In terms of R & D output, 33 clinical applications, 38 production applications, 54 clinical approvals and 2 production approvals were submitted in 2017 337 patents were applied for and 62 patents were authorized Sales revenue contributed by new products accounted for 13.1% of the group's total revenue In addition, on the theme of "consistency evaluation" throughout 2017, Zhengda Tianqing Pharmaceutical Group (hereinafter referred to as Zhengda Tianqing), the most important subsidiary of China biopharmaceutical, has also achieved milestone achievements, including: 1) tenofovir dipivoxil fumarate tablets obtained the drug registration approval for chronic hepatitis B issued by CFDA in December 2017, which is the first in China The bioequivalence study was completed in accordance with the "evaluation of the consistency of quality and efficacy of generic drugs", and the generic drugs were used in the head-to-head clinical trials with the original drugs 2) Tuotuo (rosuvastatin calcium tablet), a lipid-lowering drug, is one of the first 17 varieties to pass the consistency evaluation, and it is also the first generic drug to pass the quality consistency evaluation among similar products Rosuvastatin calcium tablets performed well in 2017, with sales revenue of 567 million yuan, an increase of 5.7% over the same period last year In its outlook, China biopharmaceutical pointed out that in 2018, the positive short-term factors of the global economic environment increased, while facing risks such as changes in trade policies, sudden deterioration of the financial environment and geopolitics Although China's economy is facing many challenges, its overall structure has been gradually optimized and the trend is stable and positive The continuous deepening of medical reform measures such as hierarchical diagnosis and treatment, two vote system, business tax instead of value-added tax, "business tax instead of value-added tax", zero addition of hospital drugs and control of the proportion of hospital revenue drugs will have a significant impact on the pharmaceutical circulation system and the pharmaceutical sales terminal structure Policies such as quality consistency evaluation, series strict control of R & D and encouragement of innovation will promote industry R & D to be more standardized and improve product quality, so as to accelerate the survival of the fittest The Group believes that the pharmaceutical industry will be generally stable in the future, with both challenges and opportunities.